AR019855A1 - Uso de conjugados de peg-ifn-alfa y ribavirina para la fabricacion de un medicamento para el tratamiento de hepatitis c cronica - Google Patents

Uso de conjugados de peg-ifn-alfa y ribavirina para la fabricacion de un medicamento para el tratamiento de hepatitis c cronica

Info

Publication number
AR019855A1
AR019855A1 ARP990102664A ARP990102664A AR019855A1 AR 019855 A1 AR019855 A1 AR 019855A1 AR P990102664 A ARP990102664 A AR P990102664A AR P990102664 A ARP990102664 A AR P990102664A AR 019855 A1 AR019855 A1 AR 019855A1
Authority
AR
Argentina
Prior art keywords
ifn
peg
manufacture
treatment
conjugates
Prior art date
Application number
ARP990102664A
Other languages
English (en)
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8232086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR019855(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR019855A1 publication Critical patent/AR019855A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ARP990102664A 1998-06-08 1999-06-04 Uso de conjugados de peg-ifn-alfa y ribavirina para la fabricacion de un medicamento para el tratamiento de hepatitis c cronica AR019855A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98110433 1998-06-08

Publications (1)

Publication Number Publication Date
AR019855A1 true AR019855A1 (es) 2002-03-20

Family

ID=8232086

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102664A AR019855A1 (es) 1998-06-08 1999-06-04 Uso de conjugados de peg-ifn-alfa y ribavirina para la fabricacion de un medicamento para el tratamiento de hepatitis c cronica

Country Status (34)

Country Link
US (3) US20030053986A1 (cg-RX-API-DMAC7.html)
EP (1) EP1087778B1 (cg-RX-API-DMAC7.html)
JP (2) JP3839667B2 (cg-RX-API-DMAC7.html)
KR (2) KR20050055053A (cg-RX-API-DMAC7.html)
CN (1) CN1170543C (cg-RX-API-DMAC7.html)
AR (1) AR019855A1 (cg-RX-API-DMAC7.html)
AT (1) ATE307597T1 (cg-RX-API-DMAC7.html)
AU (1) AU767131B2 (cg-RX-API-DMAC7.html)
BR (1) BR9911076A (cg-RX-API-DMAC7.html)
CA (1) CA2334267C (cg-RX-API-DMAC7.html)
CL (1) CL2010000828A1 (cg-RX-API-DMAC7.html)
CO (1) CO5050297A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ298681B6 (cg-RX-API-DMAC7.html)
DE (1) DE69927971T2 (cg-RX-API-DMAC7.html)
DK (1) DK1087778T3 (cg-RX-API-DMAC7.html)
ES (1) ES2251196T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20000808A2 (cg-RX-API-DMAC7.html)
HU (1) HU228218B1 (cg-RX-API-DMAC7.html)
ID (1) ID29285A (cg-RX-API-DMAC7.html)
IL (2) IL139786A0 (cg-RX-API-DMAC7.html)
MA (1) MA26641A1 (cg-RX-API-DMAC7.html)
MY (1) MY124091A (cg-RX-API-DMAC7.html)
NO (1) NO325598B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ508249A (cg-RX-API-DMAC7.html)
PE (1) PE20000560A1 (cg-RX-API-DMAC7.html)
PL (1) PL192364B1 (cg-RX-API-DMAC7.html)
RS (1) RS50144B (cg-RX-API-DMAC7.html)
RU (1) RU2271217C2 (cg-RX-API-DMAC7.html)
SA (1) SA99200208B1 (cg-RX-API-DMAC7.html)
SI (1) SI1087778T1 (cg-RX-API-DMAC7.html)
TR (1) TR200003635T2 (cg-RX-API-DMAC7.html)
TW (1) TWI241913B (cg-RX-API-DMAC7.html)
WO (1) WO1999064016A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200006814B (cg-RX-API-DMAC7.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298681B6 (cs) * 1998-06-08 2007-12-19 F. Hoffmann-La Roche Ag Lécivo pro lécení infekcí chronické hepatitis C
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
IL153020A0 (en) 2000-05-26 2003-06-24 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
EA007785B1 (ru) * 2000-08-07 2007-02-27 Сайклоун Фармасьютикалз, Инк. Способ лечения гепатита с с помощью тимозина, интерферона и рибавирина
US7179791B2 (en) 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
JP2005504087A (ja) 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
KR100480429B1 (ko) * 2001-12-04 2005-04-06 선바이오(주) 인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체
CN1678326A (zh) * 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
EP1523489B1 (en) 2002-06-28 2014-03-12 IDENIX Pharmaceuticals, Inc. Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
MXPA05006230A (es) 2002-12-12 2005-09-20 Idenix Cayman Ltd Proceso para la produccion de nucleosidos ramificados-2'.
CA2511616A1 (en) * 2002-12-23 2004-07-15 Idenix (Cayman) Limited Process for the production of 3'-nucleoside prodrugs
ES2906207T3 (es) 2003-05-30 2022-04-13 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
AU2005256963A1 (en) * 2004-06-23 2006-01-05 Centre National De La Recherche Scientifique 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
US7857760B2 (en) 2004-07-13 2010-12-28 Dexcom, Inc. Analyte sensor
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
JP5001842B2 (ja) 2004-09-14 2012-08-15 ギリアド ファーマセット エルエルシー ２’−フルオロ−２’−アルキル−置換又は他の置換されていてもよいリボフラノシルピリミジン類及びプリン類並びにそれらの誘導体の製造
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
MX2008002015A (es) * 2005-08-15 2008-03-25 Hoffmann La Roche Polietilenglicol-interferon alfa y ribavirina para el tratamiento del virus de hepatitis b.
US9201979B2 (en) * 2005-09-14 2015-12-01 Millennial Media, Inc. Syndication of a behavioral profile associated with an availability condition using a monetization platform
JP5254033B2 (ja) * 2005-12-23 2013-08-07 イデニク プハルマセウティカルス，インコーポレイテッド 分岐型ヌクレオシドを調製するための合成中間体の製造方法
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
JP5711118B2 (ja) 2008-06-24 2015-04-30 テクニッシュ ウニヴェルジテート ミュンヘン 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン
JP5539363B2 (ja) * 2008-09-17 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インターフェロンおよびリバビリンとのｈｃｖｎｓ３プロテアーゼ阻害剤の組合せ
EP2376515A1 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthesis of purine nucleosides
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
BRPI0922508A8 (pt) 2008-12-23 2016-01-19 Pharmasset Inc Análogos de nucleosídeo
JP2012526149A (ja) 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
CA2770149A1 (en) 2009-08-05 2011-02-10 Pieris Ag Controlled release formulations of lipocalin muteins
PH12012500827A1 (en) 2009-10-30 2013-01-07 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
DK2990798T3 (da) 2009-12-07 2019-12-02 Pieris Pharmaceuticals Gmbh Muteiner af human lipocalin 2 (lcn2, hngal) med affinitet for et specifikt mål
CN102858790A (zh) 2010-03-31 2013-01-02 吉利德制药有限责任公司 核苷氨基磷酸酯
JP5902679B2 (ja) 2010-06-08 2016-04-13 ピエリス アーゲーＰｉｅｒｉｓ Ａｇ ＩＬ−４Ｒαに結合する涙液リポカリンムテイン
KR20180088745A (ko) 2010-08-16 2018-08-06 피어이스 파마슈티컬즈 게엠베하 헵시딘 결합 단백질
JP6100694B2 (ja) 2010-11-15 2017-03-22 ピエリス ファーマシューティカルズ ゲーエムベーハー グリピカン−３（ｇｐｃ３）に対して親和性を有するヒトリポカリン２の突然変異タンパク質
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
DK2646552T3 (en) 2010-12-02 2017-10-23 Pieris Pharmaceuticals Gmbh MUTEINES OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR CTLA-4
HRP20180237T4 (hr) 2011-09-16 2020-12-11 Gilead Pharmasset Llc Metode za liječenje hcv-a
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013087660A1 (en) 2011-12-13 2013-06-20 Pieris Ag Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
US20140039923A1 (en) * 2012-08-03 2014-02-06 AxelaCare Health Solutions, Inc. Computer program, method, and system for receiving and managing patient data gathered during patient treatments
EP3441400B1 (en) 2012-11-19 2022-07-20 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
KR20140119012A (ko) 2013-01-31 2014-10-08 길리어드 파마셋 엘엘씨 두 항바이러스 화합물의 병용 제형물
JP6619650B2 (ja) 2013-03-14 2019-12-11 ピエリス ファーマシューティカルズ ゲーエムベーハー 新規のｐｃｓｋ９結合タンパク質
US20150064253A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
CA2936611A1 (en) 2014-01-13 2015-07-16 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
CA2949405C (en) 2014-05-22 2023-08-01 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
EP3250586B1 (en) 2015-01-28 2021-10-27 Pieris Pharmaceuticals GmbH Novel proteins specific for angiogenesis
TW201636364A (zh) 2015-02-18 2016-10-16 賽諾菲公司 對於螢光鐵載體及綠膿桿菌螯鐵蛋白具特異性之新穎蛋白
MX2017014082A (es) 2015-05-04 2018-06-28 Pieris Pharmaceuticals Gmbh Nuevas proteinas especificas para cd137.
RU2727165C2 (ru) 2015-05-04 2020-07-21 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
RU2021119777A (ru) 2015-05-18 2021-08-16 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид, способный связывать cd137 и gpc3, молекула нуклеиновой кислоты, содержащая нуклеотидную последовательность, кодирующую такой слитый полипептид, способ его получения и пути применения
US10273275B2 (en) 2015-05-18 2019-04-30 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules
CN108348573A (zh) 2015-07-15 2018-07-31 皮里斯制药有限公司 Lag-3特异性的新型蛋白
AU2016363668A1 (en) 2015-11-30 2018-05-24 Pieris Australia Pty Ltd. Novel anti-angiogenic fusion polypeptides
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
EP3571219A1 (en) 2017-01-18 2019-11-27 Pieris Pharmaceuticals GmbH Lipocalin muteins with binding affinity for lag-3
ES2948717T3 (es) 2018-07-31 2023-09-18 Pieris Pharmaceuticals Gmbh Nueva proteína de fusión específica para CD137 y PD-L1
BR112021016829A2 (pt) 2019-02-26 2021-10-19 Pieris Pharmaceuticals Gmbh Proteínas de fusão, molécula de ácido nucleico, métodos de produção, de ativar simultaneamente as vias de sinalização, de coestimular células t, de induzir uma resposta de linfócitos e de induzir o aumento da citólise, composição farmacêutica e método para prevenir, melhorar ou tratar cânceres
CA3177098A1 (en) 2020-06-05 2021-12-09 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1bb
KR20230165917A (ko) 2021-04-08 2023-12-05 피어이스 파마슈티컬즈 게엠베하 결합 조직 성장 인자(ctgf)에 특이적인 신규 리포칼린 뮤테인
WO2022243341A1 (en) 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for ox40
TW202428603A (zh) 2022-09-21 2024-07-16 美商思進公司 新穎的cd137及cd228特異性融合蛋白
WO2025175123A1 (en) 2024-02-16 2025-08-21 Seagen Inc. Methods of treating cancer using fusion proteins specific for cd137 and cd228

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4681848A (en) * 1982-09-22 1987-07-21 Takeda Chemical Industries, Ltd. Novel peptide and use thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3719046A1 (de) * 1987-06-06 1988-12-15 Basf Ag Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5238915A (en) * 1991-02-08 1993-08-24 Wakunaga Seiyaku K.K. Aromatic composition and method for controlling aroma
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
HUT75533A (en) * 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
ES2214551T3 (es) * 1995-11-02 2004-09-16 Schering Corporation Terapia de infusion continua de citocinas a baja dosis.
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
CZ298681B6 (cs) * 1998-06-08 2007-12-19 F. Hoffmann-La Roche Ag Lécivo pro lécení infekcí chronické hepatitis C

Also Published As

Publication number Publication date
NZ508249A (en) 2003-02-28
BR9911076A (pt) 2001-02-20
YU77000A (sh) 2003-08-29
ATE307597T1 (de) 2005-11-15
ZA200006814B (en) 2002-05-03
TR200003635T2 (tr) 2001-04-20
NO20006178D0 (no) 2000-12-05
JP3839667B2 (ja) 2006-11-01
SI1087778T1 (sl) 2006-02-28
PE20000560A1 (es) 2000-07-05
CO5050297A1 (es) 2001-06-27
RU2271217C2 (ru) 2006-03-10
HK1037981A1 (en) 2002-03-01
PL344794A1 (en) 2001-11-19
DE69927971D1 (de) 2005-12-01
IL139786A0 (en) 2002-02-10
US20030053986A1 (en) 2003-03-20
DE69927971T2 (de) 2006-07-27
US20070196385A1 (en) 2007-08-23
NO20006178L (no) 2000-12-05
CA2334267C (en) 2009-02-17
ES2251196T3 (es) 2006-04-16
MA26641A1 (fr) 2004-12-20
JP2006160759A (ja) 2006-06-22
EP1087778A1 (en) 2001-04-04
CZ298681B6 (cs) 2007-12-19
MY124091A (en) 2006-06-30
HUP0102033A2 (hu) 2001-10-28
ID29285A (id) 2001-08-16
JP2002517451A (ja) 2002-06-18
CN1170543C (zh) 2004-10-13
EP1087778B1 (en) 2005-10-26
KR20050055053A (ko) 2005-06-10
CA2334267A1 (en) 1999-12-16
CL2010000828A1 (es) 2011-02-11
HRP20000808A2 (en) 2001-10-31
WO1999064016A1 (en) 1999-12-16
HU228218B1 (en) 2013-02-28
KR20010052622A (ko) 2001-06-25
US20050031589A1 (en) 2005-02-10
AU767131B2 (en) 2003-10-30
DK1087778T3 (da) 2005-12-19
CZ20004487A3 (en) 2001-06-13
HUP0102033A3 (en) 2010-01-28
NO325598B1 (no) 2008-06-23
AU4503399A (en) 1999-12-30
PL192364B1 (pl) 2006-10-31
CN1305382A (zh) 2001-07-25
IL139786A (en) 2007-10-31
RS50144B (sr) 2009-03-25
TWI241913B (en) 2005-10-21
SA99200208B1 (ar) 2006-08-15

Similar Documents

Publication Publication Date Title
AR019855A1 (es) Uso de conjugados de peg-ifn-alfa y ribavirina para la fabricacion de un medicamento para el tratamiento de hepatitis c cronica
DK1204410T3 (da) Farmaceutisk doseringsform med flere komponenter
ES2186667T3 (es) Analogos de nucleosidos de 1,3-oxatiolano.
DE60126321D1 (de) Gelsystem zur ocularen verabreichung von arzneimitteln
GB9822440D0 (en) Medicaments
DE50102597D1 (de) Arzneimittel gegen virale erkrankungen
DE69917477D1 (de) Vorrichtung zur arzneistoffabgabe, insbesondere zur verabreichung von progestinen und östrogenen
EE200200607A (et) 2-atsüülindoolderivaadid ja nende kasutamine kasvajavastaste ravimitena
AR034343A1 (es) Combinaciones farmaceuticas
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
NO20011217D0 (no) Doseringsform omfattende væskeformulering
EP1299337A4 (en) HYDROXYPHENSTATIN AND ITS PROMEDICATIONS
ES2132556T3 (es) Nuevo derivado de benzo-tiadiazina, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen.
ATE348599T1 (de) Pharmazeutische dronedaron-zusammensetzung für die parenterale verabreichung
FI960850A7 (fi) Kinoksaliinien käyttö proteaasi-inhibiittoreihin yhdistettyinä lääkkeeksi AIDS:in ja/tai HIV-tartuntojen hoitamiseksi
JP2005530735A5 (cg-RX-API-DMAC7.html)
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
AR024981A1 (es) Composicion para la prevencion y el tratamiento de las disfunciones y enfermedades del rinon
NL194430B (nl) Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking.
DE69934902D1 (de) Medikament gegen drogenabhängigkeit
ITBO980239A0 (it) Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della retinopatia diabetica.
ECSP993003A (es) Uso de peg - ifn -alpha y ribavirina para el tratamiento de hepatitis c cronica
FI942803L (fi) Ipsapironi-lääkevalmiste
DE60322871D1 (de) Thaltende zubereitungen
BR0202759A (pt) Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa

Legal Events

Date Code Title Description
FC Refusal